Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nauman Moazzam (NPI 1407812043)

Field	Value
Entity Type	Individual
Organization	Nauman Moazzam
Address	11750 W. 2nd Place Suite 100
City	Lakewood
State	CO
ZIP	80228
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 22, 2006

Payer Source	Total Paid
Medicare	$3.6M
Medicaid	$0

Key Findings

This provider is effectively single-payer in scope: reported total Medicare revenue of $3.6M and no Medicaid billing on file. The absence of Medicaid activity means analysts should treat this profile as primarily Medicare-facing when assessing payer strategy and revenue sensitivity.

Revenue is highly concentrated in a small set of high-cost oncology drugs: the precomputed top three Medicare codes (J9271, J9299, J1568) account for 70.9% of the provider's Medicare revenue. Those three codes are reported as $1.5M (J9271, 44.5%), $700.3K (J9299, 20.9%), and $185.6K (J1568, 5.5%), indicating that a handful of infusible agents dominate the practice’s earnings.

The code mix and descriptions indicate a predominantly infusion-based oncology practice: J9271 (pembrolizumab) and J9299 (nivolumab) are the top revenue drivers and multiple chemotherapy administration codes (96413, 96417, 96401, 96365/96367, G0498) appear on the list. The presence of supportive agents and biosimilars (Q5118, Q5119, Q5122, J9305) and EOM monthly payments (M0010) further supports a business model centered on in-office systemic therapy and accompanying care management.

Competitive standing on key biologic agents is strong for some therapies and more ordinary for others. The provider ranks #56 of 1841 for J9271 (97th percentile), described as notably above typical national volume, while J9299 ranks #84 of 505 (84th percentile) and is characterized as typical; J9305 shows a high rank (#5 of 33, 88th percentile) but against a small national denominator. These rankings suggest national-level prominence for pembrolizumab administration and solid but less exceptional positioning for several other agents.

Several utilization measures are statistical outliers relative to national peers, highlighting unusually high volumes in both visits and chemotherapy administration. Codes flagged as "extreme outlier" or similarly high-volume include 99214 (99th percentile, extreme outlier) and 96413 (99th percentile, extreme outlier), and 85055 is listed as rank #2 (100th percentile, extreme outlier). Together these suggest significantly higher-than-typical visit complexity and infusion throughput compared with national peers.

Ancillary diagnostic and lab services are performed at appreciable volume, implying in-house or tightly integrated lab capability to support oncology care. High counts and national ranks appear for CBC (85025), CMP (80053), flow cytometry add-on 88185, routine blood draw 36415, and a notably concentrated volume for reticulated platelet testing (85055, rank #2, 100th percentile). This mix aligns with a hematology/oncology practice that both diagnoses and manages complex blood disorders alongside systemic therapy.

The provider’s NPI was enumerated on 2006-04-22 (~20 years ago), indicating a well-established presence in the market. That tenure is consistent with the observed high-volume infusion and E&M activity and suggests an established referral base and operational infrastructure needed to sustain high outpatient oncology throughput.

From a payer-management perspective, dependence on a few high-cost injectable agents creates both negotiating leverage and concentration exposure: payer actions or shifts in utilization for J9271 or J9299 could materially affect revenue given their combined share of 70.9% of Medicare revenue. Analysts should monitor utilization trends for those specific codes and related administration codes (96413, 96417, G0498) when modeling future revenue or contracting scenarios.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

97 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	35,600	$40	$1.5M
J9299	Injection, nivolumab, 1 mg	29,180	$20	$700.3K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	5,460	$30	$185.6K
J0897	Injection, denosumab, 1 mg	7,140	$20	$128.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,210	$100	$118.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,040	$100	$108.6K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	3,420	$20	$75.2K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	5,610	$10	$67.3K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	2,690	$20	$59.2K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	670	$90	$58.5K

Showing 1–10 of 97

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 97 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Nauman Moazzam — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

97 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	40	10,700	$40	$520.5K
J9299	1	10	10,930	$20	$355.1K
J1568	3	30	2,240	$30	$101.5K
J0897	13	140	2,580	$20	$68.8K
J9305	1	10	5,610	$10	$66.9K
Q5118	1	10	2,520	$20	$56.3K
Q5119	2	10	1,960	$20	$47.4K
J2506	2	10	370	$90	$32.3K
Q5122	1	10	320	$90	$30.7K
J3490	4	60	50	$290	$23.1K

Showing 1–10 of 97

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nauman Moazzam, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0
Sujatha Nallapareddy	CO	Hematology & Oncology Physician	$1.4M	$0
Manojkumar Bupathi	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Nauman Moazzam, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Walgreen Co	CO	Pharmacy	$108.9M	$19.9K
Catholic Health Initiatives Colorado	CO	General Acute Care Hospital	$0	$8.9M
Colorado Pain Practice, PLLC	CO	Pain Medicine (Anesthesiology) Physician	$0	$7.1M
Alert Response, LLC	CO	Emergency Response System Companies	$0	$5.8M
Colorado Imaging Associates P C	CO	Diagnostic Radiology Physician	$0	$5.6M
Critical Care Pulmonary And Sleep Associates Professional LLP	CO	Critical Care Medicine (Internal Medicine) Physician	$0	$5.2M
Catholic Health Initiatives Colorado	CO	Air Ambulance	$0	$4.4M
Lisa Rozo	CO	Physical Therapist	$276.2K	$1.4M
Rocky Mountain Endoscopy Centers, LLC	CO	Ambulatory Surgical Clinic/Center	$571.7K	$511.4K
Tera Sabatino	CO	Family Nurse Practitioner	$805.8K	$0

Nauman Moazzam — Billing Profile & Reimbursement Data

Sign up for Nauman Moazzam — Billing Profile & Reimbursement Data policy alerts

Nauman Moazzam — Billing Profile & Reimbursement Data

Sign up for Nauman Moazzam — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References